No Data
No Data
Express News | Gan & Lee Pharmaceuticals - Gzr18 Injections Were Safe and Well Tolerated
Express News | Gan & Lee Pharmaceuticals' Bi-Weekly (Twice a Month) GLP-1 Receptor Agonist Gzr18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase Iib Clinical Trial
Up to 20% weight loss! Eli Lilly and Co's Theralogix (Tesofensine) approved in China, stronger effect than Sibutramine?
Is the competition intensifying?
Gan & Lee Pharmaceuticals.'s (SHSE:603087) Market Cap Rose CN¥2.4b Last Week; Retail Investors Who Hold 42% Profited and so Did Insiders
Gan & Lee Pharmaceuticals (603087.SH): It is expected that the Sitagliptin phosphate tablets will be launched for sales after the expiration of the original research product patent in the second half of the year.
On July 10th, Gelonhui reported that Gan & Lee Pharmaceuticals (603087.SH) stated on its investor platform that GZR4 is a new long-acting basal insulin analogue independently developed by Gan & Lee Pharmaceuticals, designed for once-a-week administration. In addition, the Sitagliptin Phosphate Tablets is the company's first independently developed oral hypoglycemic drug, which is expected to be launched for sale after the expiration of the original patented product in the second half of 2024.
Announcement of expected increase in performance for the first half of 2024.
No Data